Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Short Interest Up 5.1% in January

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) saw a significant growth in short interest in January. As of January 31st, there was short interest totalling 644,000 shares, a growth of 5.1% from the January 15th total of 612,700 shares. Currently, 10.9% of the shares of the company are short sold. Based on an average daily volume of 33,700 shares, the short-interest ratio is presently 19.1 days.

Greenwich LifeSciences Stock Up 0.7 %

Shares of GLSI stock opened at $12.38 on Tuesday. Greenwich LifeSciences has a 12-month low of $9.91 and a 12-month high of $21.44. The stock’s 50-day moving average price is $12.58 and its 200-day moving average price is $13.44.

Insider Activity at Greenwich LifeSciences

In other Greenwich LifeSciences news, CEO Snehal Patel acquired 2,500 shares of the stock in a transaction dated Friday, January 10th. The shares were acquired at an average cost of $12.51 per share, for a total transaction of $31,275.00. Following the completion of the transaction, the chief executive officer now directly owns 5,552,502 shares of the company’s stock, valued at approximately $69,461,800.02. The trade was a 0.05 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. Over the last three months, insiders have purchased 10,500 shares of company stock worth $128,459. Corporate insiders own 51.67% of the company’s stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Wells Fargo & Company MN boosted its holdings in shares of Greenwich LifeSciences by 54.8% in the fourth quarter. Wells Fargo & Company MN now owns 2,847 shares of the company’s stock valued at $32,000 after purchasing an additional 1,008 shares during the period. Brown Brothers Harriman & Co. purchased a new stake in shares of Greenwich LifeSciences in the fourth quarter valued at approximately $45,000. JPMorgan Chase & Co. boosted its holdings in shares of Greenwich LifeSciences by 172.0% in the fourth quarter. JPMorgan Chase & Co. now owns 7,061 shares of the company’s stock valued at $79,000 after purchasing an additional 4,465 shares during the period. Bank of America Corp DE boosted its holdings in shares of Greenwich LifeSciences by 22.3% in the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock valued at $82,000 after purchasing an additional 1,322 shares during the period. Finally, Barclays PLC boosted its holdings in shares of Greenwich LifeSciences by 12.7% in the fourth quarter. Barclays PLC now owns 9,648 shares of the company’s stock valued at $108,000 after purchasing an additional 1,088 shares during the period. Hedge funds and other institutional investors own 4.16% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $38.00 price objective on shares of Greenwich LifeSciences in a research report on Tuesday, February 11th.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.